TMS Therapy Denied by Insurance? How to Appeal for Treatment-Resistant Depression

Transcranial magnetic stimulation (TMS) is a non-invasive, FDA-cleared treatment for major depressive disorder that does not respond to antidepressant medications. Despite strong clinical evidence and FDA clearance since 2008, insurance companies routinely deny TMS — often claiming it is "experimental" or that the patient has not met an arbitrary number of prior medication failures. If your TMS claim was denied, here is how to fight back.

Why Insurers Deny TMS

"Experimental or investigational" denials. The most common denial rationale is that TMS is experimental. This argument is factually wrong for major depressive disorder. The FDA cleared NeuroStar TMS in 2008, and multiple additional TMS devices have since received FDA clearance for MDD. Numerous clinical guidelines — including those from the American Psychiatric Association — recognize TMS as an evidence-based treatment for treatment-resistant depression (TRD). An "experimental" denial for TMS in 2026 is legally vulnerable.

Inadequate prior medication failures. Most insurers require evidence of failed antidepressant trials before approving TMS. The dispute is usually over the number and type of trials required. A plan requiring six or seven failed medication trials when the FDA label and clinical guidelines require fewer is applying a more restrictive NQTL than is applied to comparable medical treatments — a Mental Health Parity Act (MHPAEA) Explained" class="auto-link">MHPAEA violation.

Step therapy requirements that are not clinically supported. Some insurers require augmentation strategies (adding lithium, atypical antipsychotics, or thyroid hormone) before approving TMS. While augmentation is clinically recognized, requiring a patient to try every possible augmentation protocol before TMS may not be supported by evidence and may also violate parity.

Diagnosis mismatch. TMS has FDA clearance for MDD. Some insurers deny TMS for treatment-resistant bipolar depression, OCD, or PTSD — even though evidence supports its use in these conditions and some TMS devices carry FDA clearance for OCD specifically (cleared in 2018).

What "Treatment-Resistant Depression" Means for Insurance Purposes

TRD is generally defined as failure to respond to an adequate trial of at least two antidepressants from different classes at therapeutic doses for a sufficient duration (typically six to eight weeks). Your documentation must clearly show:

• Specific medication names, doses, and duration of each failed trial
• Reasons for discontinuation (lack of efficacy, not just side effects)
• Treating psychiatrist's clinical assessment confirming TRD diagnosis

The more precisely this is documented in your appeal, the harder it is for the insurer to deny on "inadequate prior treatment" grounds.

MHPAEA and TMS: The Step Therapy Argument

Under MHPAEA, the clinical criteria for authorizing a mental health treatment cannot be more restrictive than the criteria applied to analogous medical treatments. Ask your insurer:

• How many failed treatments are required before a cardiac patient can access an interventional cardiac procedure?
• Does the plan require documented failure of multiple medication classes before covering chemotherapy for a cancer diagnosis?

If the mental health step therapy requirements are more burdensome than those for comparable medical or surgical treatments, that is a parity violation you can document and include in your appeal.

OCD and TMS: A Separate FDA Clearance

The FDA cleared the BrainsWay Deep TMS system for obsessive-compulsive disorder in 2018. If your TMS denial is for OCD, the "experimental" argument is even weaker. An insurer denying an FDA-cleared treatment for an FDA-approved indication with an argument that it is experimental has a very difficult case to make in External Independent Review: Complete Guide" class="auto-link">external review.

Building Your TMS Appeal

Your appeal should include:

• A letter from your treating psychiatrist documenting TRD, the specific failed medication trials (names, doses, duration, outcome), and clinical rationale for TMS
• FDA clearance documentation — easily obtained from the FDA's 510(k) database or the device manufacturer
• Clinical practice guidelines from the APA or other recognized bodies supporting TMS for TRD
• A rebuttal to the specific denial rationale (experimental, insufficient prior trials, etc.)
• A MHPAEA comparative analysis request if step therapy requirements are at issue

External Review Success Rate

TMS denials fare well in external review. Independent reviewers are required to apply generally accepted clinical standards — and for TMS in treatment-resistant depression, those standards clearly support coverage. If your internal appeal is denied, request external review promptly. Many states require a decision within 45 days, and urgent cases may qualify for a 72-hour expedited review.

Fight Back With ClaimBack

TMS denials are winnable — especially when the insurer is relying on an "experimental" argument that was outdated in 2010. ClaimBack helps you build a complete, evidence-backed appeal letter that directly addresses your insurer's denial rationale.

Start your TMS appeal at ClaimBack and get the treatment you need.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied